Why is the Incannex share price spiking 8% on Tuesday?

The stock has caught a bid on Tuesday.

| More on:
A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Incannex shares have lifted today following the release of a company presentation
  • In it the company gave an in depth view of its assets and operations, including the value proposition at hand
  • In the last 12 months the Incannex share price has clipped a 5% gain

The Incannex Healthcare Ltd (ASX: IHL) share price has jumped from the opening gate on Tuesday.

At the time of writing, Incannex was trading nearly 8% higher at 28 cents a share following the release of a company presentation.

It's a welcome gain for the medicinal cannabis company which has seen its share price plunge 55% over the past few months.

The chart below shows the Incannex share price plotted against the S&P/ASX 200 Index (ASX: XJO) for the past 12 months of trading.

TradingView Chart

What did Incannex release?

The company posted an overview of its assets, operations, and unique value proposition in the presentation released today.

Incannex described its intellectual property's "six categories of opportunity".

The company said it covers a potential $290 billion addressable market estimate for its lead drug candidates and $2 billion per year in potential revenue from psychedelic treatment therapies.

One of Incannex's lead drug candidates is IHL-42X, indicated in the treatment of obstructive sleep apnoea (OSA).

The OSA devices market is valued at US$10 billion, Incannex said, and it's projected to grow at 6.2% annually.

The drug candidate has made inroads in providing a novel solution to OSA, with data from clinical trials holding up well from a safety and efficacy standpoint.

So much so, the patent application for the drug "was considered 'novel and inventive' by [the] international patent examiner", Incannex said.

Incannex also noted it had a cash position of $37.5 million as of 30 June 2022 after raising $24 million in an equity raising in Mary 2022.

Those shares were issued at 35 cents a piece, a decent notch above the company's current share price.

The Incannex share price has clipped a 4% gain these past 12 months.

Should you invest $1,000 in Dexus right now?

Before you buy Dexus shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Dexus wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Happy woman working on a laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a pleasant end to the trading week for investors this Friday.

Read more »

A happy investor sits at his desk in front of his laptop and does the mexican wave with his arms to celebrate the returns from his ASX dividend shares
Share Gainers

Why Chrysos, GQG Partners, Macquarie, and Webjet shares are storming higher today

These shares are ending the week on a positive note. But why?

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Share Gainers

The top 3 ASX 200 trades since the Liberation Day dip

These companies are up at least 35% in just over a month.

Read more »

A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
Share Gainers

Boss Energy shares have rocketed 90% in a month. Here's why

The massive rally in Boss Energy shares will be painful to the host of short sellers betting against the uranium…

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors sent the market higher once again today.

Read more »

Rising gold share price represented by a green arrow on piles of gold block.
Gold

3 reasons to buy this surging ASX All Ords gold stock today

The ASX All Ords gold stock has doubled investors’ money in 12 months, and this leading expert forecasts more outperformance…

Read more »

Two colleagues at work looking at a tablet and smiling at a rising share price.
Share Gainers

Why Generation Development, Orica, Pro Medicus, and Zip shares are storming higher today

These shares are having a strong session on Thursday. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 114% in a year, why is the Pro Medicus share price leaping higher again on Thursday?

Pro Medicus shares are back in form today and leaping ahead. Here’s why.

Read more »